Skip Content
 
Page Banner Image

DIMENSION

Sage Therapeutics.

The DIMENSION study offered by Sage Therapeutics, Inc. is investigating SAGE-718 for the treatment of cognitive symptoms associated with Huntington disease (HD) in adults with premanifest or early manifest HD. SAGE-718 has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) in September 2021 as a potential treatment for HD. Fast Track is a process designed to facilitate the development and review of new treatments for serious conditions with unmet medical need, such as HD.

DIMENSION is a Phase 2, randomized, double-blind, placebo-controlled study. The objectives of DIMENSION are to:

  • Evaluate the efficacy of SAGE-718 to reduce cognitive symptoms associated with HD
  • Evaluate the safety and tolerability of SAGE-718 in subjects with HD

The study is registered at ClinicalTrials.gov.

Status
Currently recruiting.

Study Type
Phase II Clinical Trial

Canadian Locations:

Ontario

Location: Sage Investigational Site
North York, ON  M2K 1E1
Status: Recruiting

Nova Scotia

Location: Sage Investigational Site
Halifax, NS B3S 1N2
Status: Recruiting

Quebec

Location: Sage Investigational Site
Montréal, QC H2X 0A9
Status: Recruiting

Contact: Grant Rutledge, PhD (339)-368-8432 grant.rutledge@sagerx.com

Source 

ClinicalTrials.gov

For more detailed information on this study and others and for the most recent updates, please go to clinicaltrials.gov. ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.


We support those facing huntington disease
 Latest Blog
 Questions

Questions

Have questions? Send us an email at:
E: info@huntingtonsociety.ca

 Connect
 Newsletter

Newsletter

Stay in Touch!
Enter your email address below to receive occasional updates.

Copyright © Huntington Society of Canada. All Rights Reserved. Charitable Registration Number 11896 5516 RR0001